Real-World Data for Luspatercept in Lower-Risk MDS

Opinion
Video

Valeria Santini, MD, reviews data from real-world outcomes in clinical trials investigating luspatercept in patients with lower-risk MDS.

Related Videos
Video 8 - "The Evolving Landscape of Second-Line Therapies in HCC Management"
Video 7 - "Comorbidity Considerations for HCC Treatment"
Ibrahim Aldoss, MD
Roger Li, MD, of Moffitt Cancer Center